ACS Chemical Biology · 2015 · 76 citations · 18 references
MedicineMedicinal ChemistryPharmacologyDrug DiscoveryInflammationMolecular PharmacologyAnalgesiaAnti-inflammatory PharmacologyInflammation PharmacologyMacrophage PharmacologyAnti-inflammatory TherapeuticsCysteine DegradationCysteine HydrolasesPain PharmacologyPeroxisome Proliferator-activated Receptor SignalingPeroxisome Proliferator-activated ReceptorsPharmacological Pain Reliefβ-Lactam Antibiotics
Fatty acid ethanolamides such as palmitoylethanolamide (PEA) and oleoylethanolamide (OEA) are lipid-derived mediators that potently inhibit pain and inflammation by ligating type-α peroxisome proliferator-activated receptors (PPAR-α). These bioactive substances are preferentially degraded by the cysteine hydrolase, N-acylethanolamine acid amidase (NAAA), which is highly expressed in macrophages. Here, we describe a new class of β-lactam derivatives that are potent, selective, and systemically active inhibitors of intracellular NAAA activity. The prototype of this class deactivates NAAA by covalently binding the enzyme's catalytic cysteine and exerts profound anti-inflammatory effects in both mouse models and human macrophages. This agent may be used to probe the functions of NAAA in health and disease and as a starting point to discover better anti-inflammatory drugs.
18
The PPARα–leukotriene B4 pathway to inflammation control
Pallavi R. Devchand, H. J. Keller, Jeffrey M. Peters et al. · Nature · 1996 · 1.4K citations
Jin Fu, Silvana Gaetani, Fariba Oveisi et al. · Nature · 2003 · 1.1K citations · Full text
Kazuhito Tsuboi, Yongxin Sun, Yasuo Okamoto et al. · Journal of Biological Chemistry · 2005 · 328 citations · Full text